Na Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na Li has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Yuanjing Hu
Department of Gynecologic Oncology, Tianjin Key Laboratory of human development and reproductive regulation, Tianjin Central Hospital of Gynecology Obstetrics, Nankai University Maternity Hospital, Tianjin, China
3 shared publicationsRunling Ren
Tianjin Central Hospital of Gynecology Obstetrics, School of Medicine Nankai University Tianjin China
2 shared publicationsWendi Guo
Tianjin Central Hospital of Gynecology Obstetrics, School of Medicine Nankai University Tianjin China
2 shared publications- Yuanjing Hu
Tianjin Central Hospital of Gynecology Obstetrics 1 Department of Gynecologic Oncology, /Tianjin Institute of Gynecology Obstetrics, Nankai University Maternity Hospital, Tianjin, China
2 shared publications Jingwen Si
Department of Pathology Tianjin Central Hospital of Gynecology Obstetrics Tianjin China
1 shared publication- Runling Ren
School of Medicine, Nankai University, Tianjin, 300071, China; Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin, China
1 shared publication
Latest Publications
- Open Access
- 23 June 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (11) , e70246
A Multicellular Coordinated Network Driving Lymphovascular Space Invasion in Endometrioid Endometrial Carcinoma
Lymphovascular space invasion (LVSI) is a critical factor linked to metastasis and poor outcomes in endometrioid endometrial carcinoma (EEC), yet its multicellular mechanisms remain unclear. Using single‐cell RNA sequencing of 3 LVSI‐present (LVSI+) EECs, 2 LVSI‐absent (LVSI−) EECs, and 2 normal endometrial samples, we delineated the cellular ecosystems underlying LVSI. LVSI+ EECs exhibited marked epithelial reprogramming, transitioning from differentiated ciliated epithelium to hyperproliferative and metabolically remodelled phenotypes, and contained TC4, a metastatic epithelial subset characterized by hypoxia, partial epithelial–mesenchymal transition, immunosuppression, and progesterone resistance. We also identified nine key genes in malignant epithelial cells associated with LVSI prognosis. The tumour microenvironment in LVSI+ EECs shifted from an inflammatory state dominated by epithelial cells to a collaborative network involving stromal and immune cells. This network was enriched in immunosuppressive ZNF683 + SOX4 + CD8+ T cells, Cycling_T cells, SPP1 + MMP9 + Mac, WNT5A_mCAF, Tip endothelial cells, and lymphatic endothelial cells. WNT5A_mCAF and SPP1 + MMP9 + Mac synergistically remodelled the extracellular matrix, promoted lymphangiogenesis and angiogenesis, and, together with endothelial cells, suppressed T‐cell activity via LGALS9–HAVCR2/CD44 inhibitory signalling, thereby establishing a niche conducive to vascular invasion. Using spatial multiplex immunofluorescence, we confirmed hypoxic tumour epithelial cells at the invasive front coexisting with an immunosuppressive microenvironment, and revealed spatial colocalization of PD‐L1+ tumour cells, PD‐L1+ macrophages, and PD‐1+ T cells within LVSI thrombi. Our comprehensive study provides deeper insights into LVSI as an actively coordinated multicellular process, potentially improving LVSI risk prediction, supporting treatment decision‐making, and informing new therapies targeting the tumour microenvironment.
- 23 June 2026
- Published by Wiley in Cell Proliferation
- Vol. 59 (11) , e70246
Open AccessA Multicellular Coordinated Network Driving Lymphovascular Space Invasion in Endometrioid Endometrial Carcinoma
Lymphovascular space invasion (LVSI) is a critical factor linked to metastasis and poor outcomes in endometrioid endometrial carcinoma (EEC), yet its multicellular mechanisms remain unclear. Using single‐cell RNA sequencing of 3 LVSI‐present (LVSI+) EECs, 2 LVSI‐absent (LVSI−) EECs, and 2 normal endometrial samples, we delineated the cellular ecosystems underlying LVSI. LVSI+ EECs exhibited marked epithelial reprogramming, transitioning from differentiated ciliated epithelium to hyperproliferative and metabolically remodelled phenotypes, and contained TC4, a metastatic epithelial subset characterized by hypoxia, partial epithelial–mesenchymal transition, immunosuppression, and progesterone resistance. We also identified nine key genes in malignant epithelial cells associated with LVSI prognosis. The tumour microenvironment in LVSI+ EECs shifted from an inflammatory state dominated by epithelial cells to a collaborative network involving stromal and immune cells. This network was enriched in immunosuppressive ZNF683 + SOX4 + CD8+ T cells, Cycling_T cells, SPP1 + MMP9 + Mac, WNT5A_mCAF, Tip endothelial cells, and lymphatic endothelial cells. WNT5A_mCAF and SPP1 + MMP9 + Mac synergistically remodelled the extracellular matrix, promoted lymphangiogenesis and angiogenesis, and, together with endothelial cells, suppressed T‐cell activity via LGALS9–HAVCR2/CD44 inhibitory signalling, thereby establishing a niche conducive to vascular invasion. Using spatial multiplex immunofluorescence, we confirmed hypoxic tumour epithelial cells at the invasive front coexisting with an immunosuppressive microenvironment, and revealed spatial colocalization of PD‐L1+ tumour cells, PD‐L1+ macrophages, and PD‐1+ T cells within LVSI thrombi. Our comprehensive study provides deeper insights into LVSI as an actively coordinated multicellular process, potentially improving LVSI risk prediction, supporting treatment decision‐making, and informing new therapies targeting the tumour microenvironment.
- Open Access
- 24 October 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
The rationality of negative margin criteria for conization in early cervical cancer - a cohort study
The 2023 (1st Edition) NCCN guideline changed the negative margin criteria for cervical conization from ≥ 3 mm to ≥ 1 mm. To explore the clinical safety of this up-dation in the real world, we performed a retrospective study to validate the rationality of the negative margin criteria for conization in patients with early-stage cervical cancer. We retrospectively collected the clinical and pathological data of 986 patients with early-stage cervical cancer from June 2011 to June 2023. All of the patients underwent conization and secondary (radical) hysterectomy at Tianjin Central Hospital of Gynecology Obstetrics. Patients were divided into four groups based on the status of the conization margins: margin < 1 mm (n = 132), margin < 3 mm (n = 147), margin involved (n = 443), and margin not involved (n = 264). The safety of the negative margin criteria for conization (< 1 mm) was evaluated by comparing the residual disease rates in different groups after secondary (radical) hysterectomy. Additionally, univariate and logistic multivariate analyses were conducted to identify the risk factors for residual disease after hysterectomy. A total of 986 patients with cervical cancer at stages IA1-IB1 were included. Among these patients, 382 had residual diseases (HSIL or higher) after hysterectomy, resulting in a residual disease rate of approximately 38.7%. Patients were categorized based on margin status (< 1 mm, <3 mm, margin involved, and, margin not involved). There were statistically significant differences in residual disease rates among the four groups (P < 0.05). There is no significant difference in residual disease rates between patients with the margin < 1 mm and margin < 3 mm, nor between these two groups and the margin not involved group. However, the residual disease rates in cases with margins < 1 mm and margins < 3 mm were significantly lower compared to those with margin involvement. Univariate analysis indicated that multiple factors, including age, were associated with residual disease. However, multivariate analysis revealed that age (P = 0.002, OR = 1.041, 95% CI 1.014–1.069), involvement of the margin by the lesion (P < 0.001, OR = 7.655, 95% CI 4.745–12.349), and cervical biopsy pathology showing cancer (P = 0.020, OR = 1.571, 95% CI 1.074–2.298) were independent risk factors for residual disease after hysterectomy in early-stage cervical cancer patients. Our findings suggest that a ≥ 1 mm negative margin criterion appears to be a safe threshold for early-stage cervical cancer, yet prospective validation is still required.
- 24 October 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Open AccessThe rationality of negative margin criteria for conization in early cervical cancer - a cohort study
The 2023 (1st Edition) NCCN guideline changed the negative margin criteria for cervical conization from ≥ 3 mm to ≥ 1 mm. To explore the clinical safety of this up-dation in the real world, we performed a retrospective study to validate the rationality of the negative margin criteria for conization in patients with early-stage cervical cancer. We retrospectively collected the clinical and pathological data of 986 patients with early-stage cervical cancer from June 2011 to June 2023. All of the patients underwent conization and secondary (radical) hysterectomy at Tianjin Central Hospital of Gynecology Obstetrics. Patients were divided into four groups based on the status of the conization margins: margin < 1 mm (n = 132), margin < 3 mm (n = 147), margin involved (n = 443), and margin not involved (n = 264). The safety of the negative margin criteria for conization (< 1 mm) was evaluated by comparing the residual disease rates in different groups after secondary (radical) hysterectomy. Additionally, univariate and logistic multivariate analyses were conducted to identify the risk factors for residual disease after hysterectomy. A total of 986 patients with cervical cancer at stages IA1-IB1 were included. Among these patients, 382 had residual diseases (HSIL or higher) after hysterectomy, resulting in a residual disease rate of approximately 38.7%. Patients were categorized based on margin status (< 1 mm, <3 mm, margin involved, and, margin not involved). There were statistically significant differences in residual disease rates among the four groups (P < 0.05). There is no significant difference in residual disease rates between patients with the margin < 1 mm and margin < 3 mm, nor between these two groups and the margin not involved group. However, the residual disease rates in cases with margins < 1 mm and margins < 3 mm were significantly lower compared to those with margin involvement. Univariate analysis indicated that multiple factors, including age, were associated with residual disease. However, multivariate analysis revealed that age (P = 0.002, OR = 1.041, 95% CI 1.014–1.069), involvement of the margin by the lesion (P < 0.001, OR = 7.655, 95% CI 4.745–12.349), and cervical biopsy pathology showing cancer (P = 0.020, OR = 1.571, 95% CI 1.074–2.298) were independent risk factors for residual disease after hysterectomy in early-stage cervical cancer patients. Our findings suggest that a ≥ 1 mm negative margin criterion appears to be a safe threshold for early-stage cervical cancer, yet prospective validation is still required.
- Open Access
- 18 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (3) , 109558
Corrigendum to “Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer” [Eur J Surg Oncol. 50 (2024) (11) 108522]
- 18 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (3) , 109558
Open AccessCorrigendum to “Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer” [Eur J Surg Oncol. 50 (2024) (11) 108522]
- Open Access
- 29 June 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (11) , 108522
Prognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer
- 29 June 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (11) , 108522
Open AccessPrognosis and treatment regimens for patients with different lymph node statuses in locally advanced cervical cancer
- Open Access
- 10 September 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 107071
Prognosis and adjuvant chemotherapy for patients with malignant peritoneal cytology in early-stage non-endometrioid endometrial cancer
- 10 September 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (11) , 107071
Open AccessPrognosis and adjuvant chemotherapy for patients with malignant peritoneal cytology in early-stage non-endometrioid endometrial cancer